ReiPhase 3 clinical study of oral GLP-1RA orforglipron in obesity and type 2 diabetes was successful
August 29, 2025
Source: drugdu
93
Eli Lilly recently announced positive topline results from the Phase 3 ATTAIN-2 clinical trial of its investigational GLP-1 receptor agonist orforglipron. The study targeted obese or overweight adults with type 2 diabetes. In the ATTAIN-2 study, all three dose groups of orforglipron met the primary endpoint and all key secondary endpoints, achieving significant weight loss, clinically meaningful reductions in glycated hemoglobin (A1C), and improvements in cardiovascular risk factors at 72 weeks.
Comment: Eli Lilly 's successful Phase 3 ATTAIN-2 clinical trial of orforglipron offers hope for patients with obesity and type 2 diabetes. The drug demonstrated significant weight loss and A1C reduction, while also improving cardiovascular risk factors. Oral administration is more convenient than injectable GLP-1RAs. If approved for marketing, it has the potential to reshape the treatment landscape, transform patient lifestyles, and usher in new market trends.
https://finance.eastmoney.com/a/202508273495486977.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- Multiple batches of quadrivalent influenza virus split vaccine have been sub-packaged and submitted for lot release approval; expected to be released to the market soon after approval December 12, 2025
- Ab&B Bio-Tech CO., LTD. JS Lyophilized Human Rabies Vaccine Initiates Phase III Clinical Trials December 12, 2025
- The ‘Sweetest’ HPV Vaccine Market is Gone | Haibin Interview December 12, 2025
- InnoCare Pharma announced that its first independently developed next-generation TRK inhibitor, zoletrazinib, has been approved for marketing in China December 12, 2025
- Is PD-1/VEGF dual antibody + ADC becoming the standard configuration? December 12, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
